June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Functional Visual Outcome of 1st vs 2nd Affected Eye in Treated LHON Patients at 1 Year
Author Affiliations & Notes
  • Michael Ammar
    USC Eye Institute, University of Southern California, Los Angeles, CA
  • Jasdeep S Chahal
    USC Eye Institute, University of Southern California, Los Angeles, CA
  • Amitha Ganti
    USC Eye Institute, University of Southern California, Los Angeles, CA
  • Jeffrey S Tran
    USC Eye Institute, University of Southern California, Los Angeles, CA
  • Edward Rickie Chu
    Doheny Eye Institute, Los Angeles, CA
  • Alexander Francis Chen
    USC Eye Institute, University of Southern California, Los Angeles, CA
  • Tiffany Hwang
    USC Eye Institute, University of Southern California, Los Angeles, CA
  • Rustum Karanjia
    Ophthalmology, University of California at Los Angeles, Los Angeles, CA
    Doheny Eye Institute, Los Angeles, CA
  • Alfredo A Sadun
    Ophthalmology, University of California at Los Angeles, Los Angeles, CA
    Doheny Eye Institute, Los Angeles, CA
  • Footnotes
    Commercial Relationships Michael Ammar, None; Jasdeep Chahal, None; Amitha Ganti, None; Jeffrey Tran, None; Edward Chu, None; Alexander Chen, None; Tiffany Hwang, None; Rustum Karanjia, None; Alfredo Sadun, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 3860. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Michael Ammar, Jasdeep S Chahal, Amitha Ganti, Jeffrey S Tran, Edward Rickie Chu, Alexander Francis Chen, Tiffany Hwang, Rustum Karanjia, Alfredo A Sadun; Functional Visual Outcome of 1st vs 2nd Affected Eye in Treated LHON Patients at 1 Year. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):3860. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Leber’s Hereditary Optic Neuropathy (LHON) is a mitochondrial optic neuropathy with no definitive therapy. Involvement of the first eye is usually followed by the second eye within a few months. Thus, the second eye is exposed to systemic treatment, such as quinone therapy, earlier relative to its onset. We carried out a retrospective chart review to test our hypothesis that functional visual outcome is better in the 2nd affected eye at 1 year in treated LHON patients.

Methods: Charts from 2009 to 2014 were analyzed at a university affiliated eye institute. Patients were diagnosed with LHON, and were seen at 1 year ± 2 months after conversion for the 2nd eye. 20 patients were identified and all were given quinone therapy for the duration of the year. 14 began treatment after both eyes were affected (hence earlier for 2nd eye) and 6 began after one eye was affected (hence before visual loss in the 2nd eye). Average time to treatment after involvement of the 1st eye was 172 days. LogMAR visual acuity (VA), retinal nerve fiber layer (RNFL) thickness, and mean deviation (MD) were recorded for 1st and 2nd eyes affected. A two-tailed Student’s t-test was used for statistical analysis.

Results: At 1 year in the 1st affected eye, patients treated after both eyes were affected had an average VA of 1.73 ± 1.67, an average MD of -21.44 ± 7.39, and an average RNFL thickness of 64.75 ± 13.25. In the 2nd affected eye, they had an average VA of 1.78 ± 1.77, an average MD of -15.82 ± 11.93, and an average RNFL thickness of 66.13 ± 10.97. At 1 year in patients treated after both eyes were affected, P values for the 1st vs 2nd affected eye were 0.4546 for VA, 0.1768 for MD, and 0.5342 for RNFL thickness. At 1 year in the 1st affected eye, patients treated between affected eyes had an average VA of 2.00 ± 2.08, an average MD of -29.08 ± 3.17, and an average RNFL thickness of 65.60 ± 11.01. In the 2nd affected eye, they had an average VA of 1.93 ± 2.10, an average MD of -24.22 ± 4.99, and an average RNFL thickness of 60.20 ± 9.73. At 1 year in patients treated between affected eyes, P values for the 1st vs 2nd affected eye were 0.1620 for VA, 0.1556 for MD, and 0.1540 for RNFL thickness.

Conclusions: In this LHON cohort, there was a trend but no statistically significant difference in visual outcome between the 1st and 2nd affected eye at 1 year. Hence, the timing of quinone therapy does not appear to be critical.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×